Luxeptinib is under clinical development by Aptose Biosciences and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Refractory Acute Myeloid Leukemia have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Luxeptinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CG-806 is under development for the treatment of relasped/refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), r/r chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenstrom Macroglobulinemia, mantle cell lymphoma, follicular lymphoma and diffuse large B-cell lymphoma. It is a pan-FLT3/BTK inhibitor and act by targeting FLT3 (FMS-like tyrosine kinase 3) and brew button tyrosine kinase (bruton tyrosine kinase, BTK) along with CSF1R, PDGFRα, TRK, AURK, others. It is administered through the oral route. The drug candidate is developed based on a combination of soluble protein solution (SPS), structural chemo proteomics (SCP), structural-based drug factory (SDF) platforms.
Aptose Biosciences overview
Aptose Biosciences (Aptose) is a clinical-stage biotechnology company that focuses on developing personalized therapies for the treatment of life-threatening cancers including, acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), certain B-cell malignancies, and other hematologic malignancies. The company’s cancer therapeutics pipeline products include HM43239, a myeloid kinome inhibitor (MKI), CG-806, a FLT3/BTK kinase inhibitor; APTO-253, a MYC oncogene inhibitor and APL-581, a dual BET Bromodomain-Kinase Inhibitor. Its small molecule cancer therapeutics pipeline product programs are designed to provide single agent benefit. The company operates in Canada and the US and has collaborations with biopharmaceutical companies and healthcare centers for the development and commercialization of its pipeline product programs. Aptose is headquartered in San Diego, California, the US.
For a complete picture of Luxeptinib’s drug-specific PTSR and LoA scores, buy the report here.